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Abstract 
Background: Venous thromboembolism, a potential complication of total joint replacement, is associated with 
preventable mortality and morbidity and is likely to be influenced by host-related factors such as 
sociodemographic characteristics, body mass index, medical and surgical histories, as well as circulating 
biomarkers. We conducted a systematic review and meta-analysis to assess the associations between host-
related factors and venous thromboembolism risk following total hip and knee replacements. 
Methods: We searched MEDLINE, Embase, Web of Science, and Cochrane Library to March 2018 for 
longitudinal studies reporting these associations. Summary measures of association were relative risks (95% 
confidence intervals).  
Results: We identified 89 studies with data on 14,763,963 joint replacements and 150,086 venous 
thromboembolism events. Comparing males to females, age ≥70 to <70 years, and blacks to whites, relative 
risks for venous thromboembolism were 0.83 (0.75-0.91), 1.24 (1.03-1.50), and 1.26 (1.20-1.31) respectively. 
Comparing body mass indices ≥25 vs. <25; ≥30 vs. <30; and ≥50 vs. <50 kg/m2, relative risks were 1.40 
(1.24-1.57); 1.65 (1.23-2.22); and 1.72 (1.10-2.67) respectively. Histories of venous thromboembolism; 
cardiovascular disease; congestive heart failure; cardiac arrhythmia; chronic pulmonary disease; 
coagulopathy; neurological disease; fluid & electrolyte imbalance; bariatric surgery; and comorbidity indices 
were associated with increased venous thromboembolism risk. Comparing a total knee with a hip replacement, 
relative risk for venous thromboembolism was 1.69 (1.32-2.15). 
Conclusions: Enhanced venous thromboembolism prophylaxis should be considered in those with 
nonmodifiable risk factors such as older black female knee replacement patients. Modifiable risk factors such 
as high body mass index and fluid & electrolyte imbalance should be addressed prior to elective surgery.  
 
Systematic review registration: PROSPERO 2018: CRD42018089625 
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1. Introduction 
Total joint replacement (TJR) remains one of the most successful and common orthopedic interventions. In 
the United Kingdom alone, approximately 96,000 hips and 104,000 knees were replaced during 2016.(1) 
Despite the marked benefits of arthroplasty, which include reduced pain, improved function and quality of 
life, joint replacement carries a high risk of complications including wound infection, implant failure, and 
importantly venous thromboembolism (VTE). Without sufficient thrombophylaxis, VTE (comprising of deep 
vein thrombosis [DVT] and pulmonary embolism [PE]) can occur in up to 60% of patients within 7-14 days 
after undergoing major orthopedic surgery.(2) About one-third of patients with DVT will develop a PE, which 
can cause sudden death in up to 34% of patients.(3)  
The risk of VTE has been reduced by thromboprophylactic protocols which typically involve physical or 
mechanical measures, such as graduated or pneumatic compression stockings, and/or pharmacological 
thromboprophylaxis, commonly in the form of anticoagulants.(4, 5) Despite the implementation of these 
protocols, VTE still remains a significant complication following TJR. VTE increases resource expenditure in 
healthcare and is a preventable cause of death and morbidity, with long-term sequalae including pulmonary 
hypertension, recurrent VTE and post-thrombotic syndrome.(6) As such, there is a need to identify those at a 
greater risk of developing VTE following TJR, to aid in the implementation of more efficacious preventative 
strategies.  
The literature is a minefield of studies of different designs that have reported on the associations of several 
established and emerging risk factors with VTE development following joint replacement. Host-related 
factors such as sociodemographic characteristics, anthropometric measures, past medical or surgical history 
and circulating levels of VTE-related blood biomarkers, may play a crucial role in influencing the risk of 
developing VTE following TJR, but the nature and magnitude of their associations are uncertain. Studies to 
date poorly quantify the magnitude of the associations because of their small sample sizes and inadequate 
adjustment for confounders. A number of published reviews have also attempted to aggregate the existing 
data, but with several drawbacks. Zhang et al.(7) evaluated the associations of a number of risk markers with 
VTE in patients who underwent total hip and knee replacement in 14 studies; however, this review evaluated 
only 10 factors and inadequate attempts at subgroup analysis were made. Similarly, Yi et al.(8) conducted a 
meta-analysis involving 16 studies reporting the associations of preoperative comorbidities (past medical 
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history) with VTE risk. In addition to limitations such as (i) the few number of pooled studies which did not 
provide adequate power to evaluate the associations; (ii) focus on a limited number of potential host factors, 
especially past medical history; and (iii) failure to adequately explore potential sources of heterogeneity 
among the contributing studies using formal tests; none of the reviews assessed for preferential publication 
bias or small study effects. Furthermore, no reviews have reported on the associations of circulating baseline 
preoperative circulating blood biomarkers such as glucose, albumin, and C-reactive protein with risk of VTE. 
Finally, several relevant individual reports have been published since the publication of these previous 
reviews. 
Given these limitations and the uncertainty in the evidence, there is a need to improve our understanding of 
host-related factors that contribute to VTE, which could aid in stratifying those at high risk following TJR and 
help tailor preventive strategies. In this context, we aimed to assess in greater detail than ever before, the 
nature, magnitude, and specificity of the associations of several host-related factors (sociodemographic 
characteristics, anthropometric measures, medical and surgical histories, and circulating blood markers) with 
the risk of VTE following TJR, using a systematic meta-analytic approach.  
 
2. Methods 
2.1. Data sources and search strategy 
This review was conducted in accordance with PRISMA and MOOSE guidelines (Appendices A-B) using a 
pre-defined protocol which was registered with the prospective register of systematic reviews, PROSPERO 
(CRD42018089625). We systematically searched MEDLINE, Embase, Web of Science and Cochrane 
databases for studies reporting host-related factors with the incidence of VTE following TJR. The search was 
restricted to human studies conducted in the English language and included those published from the date of 
inception of each database to 28 March 2018. Full details of the search strategy are reported in Appendix C. 
The titles and abstracts of all potentially relevant studies were screened and the full-text articles were accessed 
for the relevant studies to determine whether they fulfilled our eligibility criteria. Furthermore, the reference 
lists of the full-text articles were manually assessed to identify any studies that were not identified by our 
original search. Any disagreements in whether a study should be included were discussed by two reviewers 
and an agreement reached with consensus of a third reviewer. 
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2.2. Eligibility criteria 
Studies were included in our analyses if they were longitudinal studies (prospective or retrospective case-
control/cohort, case-cohort, nested-case control, or clinical trials) that reported the association of any host-
related factor, such as: (i) sociodemographic characteristics; (ii) anthropometric measures [weight, height, or 
body mass index (BMI)]; (iii) past medical and/or surgical history; or (iv) circulating blood biomarkers, with 
VTE following TJR (including primary or revision total replacement of the hips and knees). Since VTE cases 
may begin intraoperatively, with about 90% of cases occurring within the first post-operative week(9)  and 
other cases developing long after surgery,(10) studies were eligible if they reported follow-up of any duration. 
Outcome was defined as any VTE, including either DVT or PE. Given that our aim was to evaluate patient- or 
host-related factors that could potentially be used to predict the risk of VTE, the administration of 
thromboprophylaxis for VTE prevention was not evaluated as we consider it a surgery-related factor and 
hence it is outside the scope of this exercise. Moreover, given that there exist several prophylactic regimens 
for VTE prevention, it is a huge research topic and should be considered on its own.  
 
2.3. Data extraction and quality assessment 
Two independent authors performed data extraction using a pre-designed, standardized, data collection 
spreadsheet. We attempted to contact the authors of any study where further information was required. In the 
scenario where the same cohort had been described in multiple publications, the study with the most up-to-
date or comprehensive information was included. The quality of each study was assessed using the nine-star 
Newcastle-Ottawa Scale (NOS), a validated tool for assessing the quality of non-randomised studies included 
in systematic or meta-analytic reviews. NOS measures the quality of evidence from a score of zero to nine, 
based on three pre-defined domains including: (i) selection of participants; (ii) comparability; and (iii) 
ascertainment of outcomes of interest.  
 
2.4. Statistical analyses 
Relative risk (RRs) with 95% confidence intervals (CIs) was used as the common and summary measure of 
association across studies (risk estimates). Hazard ratios (HRs) and odds ratios (ORs) were assumed to 
approximate the same measure of RR following Cornfield’s rare disease outcome assumption.(11) Fully-
 6 
 
adjusted risk estimates were used if available, otherwise crude RRs were estimated from studies that provided 
raw counts. To ensure consistency in the pooling approach and enhance comparability and interpretation of 
the findings, reported study-specific RRs (e.g. per 10 unit change) were transformed to a common scale (per 
unit change) before pooling where possible, using standard statistical methods reported previously.(12) The 
inverse variance-weighted method was used to combine summary measures using pre-specified random-
effects models to minimize the effect of heterogeneity. Heterogeneity was assessed using the Cochrane χ2 
statistic and the I2 statistic. Several pre-defined study-level characteristics which may explain heterogeneity 
were evaluated using stratified analysis and random effects meta-regression. Funnel plots and Egger’s 
regression symmetry tests were used to assess publication bias or small study effects. All statistical analyses 
were two-sided and performed with STATA release 15 (Stata Corp, College Station, Texas, USA), where 
statistical significance was regarded as a p-value<0.05.   
 
3. Results 
3.1. Study identification and selection 
The literature search strategy identified 4,100 potentially relevant articles. After the initial screening of titles 
and abstracts, 185 articles remained for full text evaluation. Following detailed evaluation, 96 articles were 
excluded. The remaining 89 articles corresponding to 89 observational studies met the inclusion criteria and 
were included in the review (Figure 1; Table 1; Appendix D).  
 
3.2. Study characteristics and study quality 
Table 1 provides a summary of key characteristics of studies included in the review. Appendix E summarizes 
the key characteristics and quality assessment scores of the 97 individual studies. Overall, the studies involved 
approximately 14,763,963 patients or hip and knee replacements and 150,086 VTE cases. The average 
baseline age of participants in the included studies ranged from 50.9 to 76.3 years. All studies were 
observational studies. The mean follow-up for VTE outcomes ranged from 2 days to 3.2 years. 
Methodological quality of included studies ranged from 6-9.   
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3.3. Associations of sociodemographic characteristics with VTE risk 
The associations of several sociodemographic characteristics with risk of VTE are reported in Figure 2. Older 
age was associated with an increased risk of VTE when evaluated as the following risk comparisons: per one-
year increase (8 studies) as well as when comparing patients ≥70 years with those <70 years (8 studies); RRs 
(95% CIs) of 1.03 (1.02-1.05) and 1.24 (1.03-1.50) respectively. Comparing males to females in 48 studies, 
the pooled variably adjusted RR (95% CI) for VTE was 0.83 (0.75-0.91) (Figure 2; Appendix F). There was 
evidence of substantial between-study heterogeneity in the gender analysis (I2 =87%; 95% CI 83, 89%; 
p<0.001), which was partly explained by location (p for meta-regression = 0.02); study design (p for meta-
regression = 0.02); and size of study (p for meta-regression = 0.01) (Appendix G). In pooled analysis of three 
studies, black race was associated with an increased VTE risk compared to white race, RR (95% CI) 1.26 
(1.20-1.31). Comparing smokers with non-smokers (5 studies), there was a decreased risk of VTE RR (95% 
CI) 0.62 (0.47-0.82) with no evidence of heterogeneity between contributing studies (I2 =0%; 95% CI 0, 79%; 
p=0.69). There was no evidence of any statistically significant associations of VTE with alcohol abuse (1 
study)(13) and pre-operative air travel (1 study).(14) Drug abuse was associated with an increased VTE risk in 
one study.(13) 
 
3.4. Associations of anthropometric measures with VTE risk 
The associations of BMI categories with VTE risk were reported in 26 unique studies (Figure 3). In pooled 
analysis of seven studies, the RR (95% CIs) for VTE comparing BMI ≥25 vs. <25 kg/m2 was 1.40 (1.24-1.57). 
The pooled variably adjusted RR (95% CI) for VTE for individuals with a BMI ≥30 vs. <30 kg/m2 was 1.65 
(1.23-2.22) in 16 studies (Figure 3; Appendix H). There was evidence of substantial between-study 
heterogeneity in the contributing studies (I2 =96%; 95% CI 95, 97%; p<0.001), which was partly explained by 
type of VTE event (p for meta-regression = 0.01) (Appendix I). The pooled RR (95% CIs) for VTE in three 
studies comparing BMI ≥50 vs. <50 kg/m2 was 1.72 (1.10-2.26). Comparing BMIs ≥40 vs. <40 and ≥35 vs. 
<35 kg/m2, there were no significant associations with VTE risk. One study comparing underweight vs. 
morbidly obese patients (BMI <18.5 vs. 40-49 kg/m2) reported a RR (95% CI) of 3.10 (1.12-8.57) for VTE. In 
another study comparing underweight vs. patients with normal BMI (<18.5 vs. 18.5-25 kg/m2), there was no 
evidence of a significant association with VTE. In pooled analysis of two studies, a unit increase in BMI was 
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not associated with risk of VTE. Only one study assessed the association between weight and VTE risk. 
Comparing weight >65 vs. ≤65 kg, the RR (95% CI) for VTE was 0.85 (0.64-1.14). 
 
3.5. Medical and surgical history and VTE risk 
Fifty-six studies reported on the associations between several medical and surgical history characteristics with 
risk of VTE (Figure 4). Comparing patients with a history of diabetes vs. no diabetes, pooled analysis of 19 
studies showed no evidence of an association with VTE risk RR (95% CI) 0.98 (0.86, 1.11) (Figure 4; 
Appendix J). There was evidence of substantial between-study heterogeneity (I2 =72%; 95% CI 56, 82%; 
p<0.001) and which was partly explained by study location (p for meta-regression = 0.01) (Appendix K). In 
pooled analysis of 15 studies comparing a history of VTE vs. none, there was an increased risk of VTE, RR 
(95% CI) 2.58 (1.47, 4.53) (Figure 4; Appendix L) with substantial heterogeneity between contributing 
studies (I2 =95%; 95% CI 94, 97%; p<0.001). Average baseline age (p for meta-regression<0.001); type of 
VTE outcome (p for meta-regression<0.001); and degree of adjustment (p for meta-regression=0.03) partly 
explained the heterogeneity (Appendix M). 
In pooled analyses of available studies, histories of CVD; congestive heart failure (CHF); cardiac arrhythmia; 
chronic pulmonary disease (CPD); renal disease and neurological disease were each associated with an 
increased risk of VTE. There were marginally significant associations of histories of cancer and chronic 
kidney disease (CKD) with increased risk of VTE. In pooled analysis of 14 studies, patients who had a total 
knee replacement (TKR) had an increased risk of VTE compared to those who had total hip replacement 
(THR), RR (95% CI) 1.69 (1.32-2.15) (Figure 4; Appendix N). There was evidence of substantial between-
study heterogeneity between the contributing studies (I2 =97%; 95% CI 95, 97%; p<0.001). In results of single 
reports, there was evidence of statistically significant associations of VTE with histories of having coronary 
artery bypass graft (CABG), angioplasty, or stenting; haemophilia; urinary tract infection (UTI); epilepsy; 
coagulopathy; peripheral vascular disease (PVD); stroke; lymphoma; and fluid & electrolyte imbalance. 
In evaluation of other medical and surgical characteristics, Charlson Comorbidity Index (CCI) (≥3 vs. 0) and 
previous bariatric surgery (compared with BMI >40 or <25) were each associated with an increased risk of 
VTE (Figure 5). Except for a single reported which demonstrated an increased risk of VTE with rheumatoid 
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arthritis, none of the evaluated surgical indications for joint replacement (osteoarthritis and osteonecrosis) was 
significantly associated with VTE risk. 
 
3.6. Circulating blood biomarkers and VTE risk 
Seven relevant studies reported on the associations between a number of circulating blood biomarkers 
measured before joint replacement and the risk of VTE following TJR. RRs (95% CIs) for these associations 
are reported in Appendix O. One study reported increased circulating homocysteine to be associated with an 
increased risk of VTE and another study reported pre-operative glucose levels of ≥ 11.1 vs. <6.1 mmol/l to be 
associated with an increased risk of VTE. One study reported increased haemoglobin (Hb) to be associated 
with decreased risk of VTE.  
 
3.7. Publication bias 
Funnel plots for all analyses that involved ten or more studies were all symmetrical under visual examination, 
with the exception of studies that evaluated associations of history of diabetes, history of VTE, and history of 
hypertension with risk of VTE (Appendix P). The results were consistent with Egger’s regression tests 
showing little evidence of publication bias for all analyses except for the associations of histories of diabetes, 
VTE, and hypertension with risk of VTE. 
 
4. Discussion 
4.1. Key findings 
This systematic review and meta-analysis of the published literature has identified and summarized the 
associations of a comprehensive list of host-related factors (sociodemographic and anthropometric factors, 
past medical and surgical history, and pre-operative circulating blood biomarker levels) with the incidence of 
VTE following TJR. With respect to sociodemographic factors, there was a significantly higher risk of VTE 
following TJR with increasing age; in females compared with males, and in black compared with white 
patients. No associations were observed for smoking status, alcohol consumption, drug abuse or pre-operative 
air travel. On evaluation of anthropometric measures, except for these BMI comparisons ≥40 vs. <40 and ≥35 
vs. <35 kg/m2, comparisons that involved cut-offs of >25 kg/m2 or higher were significantly associated with 
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an increased risk of VTE. One study compared underweight with morbidly obese patients and reported an 
increased risk of VTE. On the role of medical and surgical history, a significantly higher incidence of VTE 
was reported for the following: previous history of VTE; CVD; CHF; cardiac arrhythmia; CPD; coagulopathy; 
neurological disease; fluid & electrolyte imbalance; raised CCI (≥3 vs. <3 and per unit increase); ASA score 
(≥2 vs. <2); previous bariatric surgery; and TKR compared with THR. Results from single reports highlighted 
increased VTE risk with a history of UTI, haemophilia, or epilepsy; whereas VTE risk was decreased in those 
with a history of CABG, angioplasty, or stenting. We found no associations between VTE risk and any of the 
evaluated surgical indications for joint replacement. Findings on the associations between circulating blood 
biomarkers and VTE risk were based on single reports. Elevated homocysteine and glucose were each 
associated with VTE risk; haematocrit with a reduced risk of VTE; and haemoglobin with both an increase 
and decrease in VTE risk.  
 
4.2. Comparison with previous work 
A number of meta-analyses have attempted to evaluate the associations of a variety of host factors with VTE 
risk following TJR. Zhang et al.(7) in their pooled analysis of 14 studies comprising of 1,723,350 joint 
replacements, evaluated only 10 factors. Consistent with our results, they reported significant associations 
with age, black race, gender, previous history of VTE and no association with diabetes mellitus. They also 
reported associations with varicose veins, hypertension, and active cancer, findings not observed in our study 
which was based on a larger number of studies and participants. Finally, though they reported obesity to be 
associated with VTE risk, our assessment was based on several BMI categories. Yi et al. al.(8) in pooled 
analysis of 16 studies including 7,395,847 patients, reported some associations which were consistent with our 
findings: significant associations for CVD, previous history of VTE, neurological disease, ASA ≥3 vs. <2 and 
null associations for malignant disease, respiratory disease, urinary & kidney disease, coronary artery disease 
(CAD), endocrine disease, and haematological disease. Their study identified significant heterogeneity for the 
pooled results, but these were not explored. Finally, Saleh et al.(15) in their narrative review of 14 articles 
relating to shoulder replacement, reported a previous history of VTE, thrombophilia, major surgery, advanced 
age (>60 years), active cancer, immobility and bed confinement to be associated with an increased risk of 
VTE. Overall, though some of our findings concur generally with previous reports on the topic, our 
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assessment includes a wide-ranging array of host factors previously not evaluated. We also conducted 
subgroup analyses by relevant study level characteristics to investigate for sources of heterogeneity. 
 
4.3. Possible explanations for findings 
A number of mechanisms may account for some of the associations demonstrated. Older age, which is an 
established risk factor for VTE, is associated with several prothrombotic factors, including multiple 
comorbidities, reduced post-operative mobility, venous valve dysfunction, increased blood viscosity and 
vascular sclerosis.(16) It has been reported that VTE risk approximately doubles every 10 years.(17) The role 
of gender in venous thromboembolism is a controversial one. However, it has been reported that the increased 
risk seen in women may be related to the use of hormonal therapy and pregnancy, although pregnancy is 
highly unlikely in cohorts undergoing elective joint replacement, who have a median age of approximately 68 
years.(1) The increased risk of VTE associated with black race may be linked to the higher prevalence of VTE 
risk factors such as obesity, hypertension and diabetes in these populations. None of the studies compared 
VTE risk in the Asian race; however, evidence suggests VTE risk is lowest in people of Asian descent 
compared with whites and African-Americans.(18) The risk is highest in African-Americans(19) and this has 
been attributed to the presence of genetic and acquired thrombophilia, principally Factor V Leiden mutation in 
African-Americans.(20) Though there exists a relationship between BMI and VTE risk, the contributions of 
the various cut-offs have not been consistent, with disparities in the literature thought to result from variations 
in the definition of obesity.(21) It has been postulated that those with a higher BMI are at increased risk of 
VTE following TJR due to a combination of prothrombotic factors including slow mobilisation following 
surgery, an underlying inflammatory state, suboptimal thromboprophylatic dosing and physical restriction to 
venous return.(22) Despite lowering pre-operative BMI, previous bariatric surgery was associated with 
increased VTE risk. Bariatric surgery is associated with gastrointestinal malabsorption, which may lead to a 
longer in-hospital recovery period and delayed wound healing,(23) subsequently leading to an increased risk 
of VTE. Our results showed a strong association of a previous history of VTE with the risk of post-operative 
VTE, and this has been postulated to be due to previous endothelial damage and/or the presence of genetic or 
acquired thrombophilia in these patients.(22) A history of cardiovascular pathology including CVD, 
arrhythmia, and CHF was associated with an increased VTE risk, which is not a surprising finding given that 
 12 
 
VTE is closely linked with CVD(24) and both conditions share common antecedent risk factors.(25) 
Neurological conditions such as cerebrovascular disease and dementia are regarded as strong risk markers for 
VTE(26) and postulated mechanisms underlying the associations include poor mobilisation and systemic 
inflammation following cerebral injury.(27) Though Zhang and colleagues(7) previously found an association 
between active malignancy and VTE risk, we did not find this in our study despite the inclusion of several 
other studies in the pooled analysis. The heterogeneity of different cancer types including the stage, grade and 
treatment history in these patients may account for the differential findings. We report a higher incidence of 
VTE following TKR compared to THR. TKR tends to be associated with an increased DVT risk in 
comparison to THR, possibly due to the use of tourniquet in TKR, but not in THR. However, THR has a 
stronger association with proximal DVTs and have greater clinical significance as these thrombi are more 
likely to progress to PE and are more often fatal, whereas distal DVTs are more likely to resolve 
spontaneously and may be clinically silent.(28) In our evaluation of pre-operative circulating blood 
biomarkers, we identified an increased risk of VTE with increased homocysteine levels in one study. 
Circulating homocysteine is emerging as a novel risk factor for vascular pathology. As the intermediary 
metabolic product of methionine, homocysteine may be involved in thrombogenesis through altered platelet 
function and enhanced blood coagulability.(29) The associations of haematological markers (haemoglobin and 
haematocrit) with VTE risk were conflicting. It has been reported that some haematological conditions such as 
polycythaemia rubra vera and other myeloproliferative neoplasms are associated with higher VTE risk,(30) 
but more studies are needed to investigate these associations in patients who undergo TJR.  
 
4.4. Implications of our findings  
With an aging population and a growing burden due to osteoarthritis, it is projected that there will be a large 
increase in the numbers of TJRs being performed worldwide over the coming decades.(31) As a serious 
consequence of TJR surgery, VTE incidence is expected to rise proportionately. The current findings highlight 
potentially host modifiable VTE risk factors as well as factors that can be easily assessed prior to joint 
replacement surgery. It has recently been shown that very few VTE risk prediction scores that aid in VTE risk 
stratification in lower limb joint replacement patients exist for use in clinical practice and these have not been 
well validated.(32) In addition to established VTE risk factors, some of the factors we have identified have the 
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potential to be used to identify patients who are at high risk of VTE and can also be combined within risk 
prediction scores or prognostic models to predict VTE outcome risk for individuals.  
 
4.5. Study strengths and limitations 
This systematic review and meta-analysis has several strengths compared to other relevant reviews on the 
topic. To our knowledge, the current study is the most comprehensive analysis of host-related factors for VTE 
following TJR. Compared to previous reviews, we had enhanced power to assess the associations in greater 
detail. We were also able to standardize and harmonize the reported associations (to a common scale) from 
some contributing studies before pooling, which ensured consistency and enhanced interpretation. In analyses 
that involved 10 or more studies, formal tests including subgroup analysis by study size, were unable to detect 
publication bias for the majority of the analyses. Some notable limitations to our current study deserve 
mention. There was significant heterogeneity among contributing studies in some of the analyses; however, 
these were investigated systematically by employing detailed sub-group analysis of pre-defined study-level 
characteristics and random effects meta-regression. We were unable to characterize the shape of any dose-
response relationships between some host factors (e.g., BMI) and VTE, given our use of published data and 
lack of consistent reporting by included studies. Some of our findings were based on single or few reports, 
hence they need interpretation with caution and also need replication in further studies. In addition, due to 
inadequate data, we were unable to explore the associations by whether DVT was asymptomatic or 
symptomatic. Inherent limitations that could have influenced our findings include errors in coding past 
medical or surgical history by the individual studies and that all 97 included studies were observational 
studies.  
 
5. Conclusions 
This aggregate published data comprising the largest number of patients on the topic to date, highlights the 
potential role of several host-related factors in the development of VTE following TJR. Our analyses 
identified VTE to be associated with sociodemographic characteristics and anthropometric measures including 
older age, female sex, increasing BMI and black race. Histories of VTE, CVD, CHF, cardiac arrhythmia, 
CPD, coagulopathy, neurological disease, fluid & electrolyte imbalance, bariatric surgery, and other indices of 
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comorbidity were each associated with increased VTE risk; as was total knee vs. total hip replacement 
surgery. Enhanced VTE prophylaxis should be considered in those with nonmodifiable risk factors such as 
older black female knee replacement patients. Modifiable risk factors such as high BMI and fluid and 
electrolyte imbalance should be addressed prior to elective surgery. The clinical utility of these factors as 
potential risk assessment tools and causal therapeutic targets for VTE also warrant investigation. 
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Figure 2. Sociodemographic characteristics comparisons and risk of venous thromboembolism 
Age
Per 1 year increase in age
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Gender
Males vs females
Race
Blacks vs whites
Smoking status
Smokers vs non-smokers
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RR (95% CI)
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Relative Risk (95% CI)
 
CI, confidence interval (bars); RR, relative risk; *, are number of participants or joint replacements 
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Figure 3. Body mass index comparisons and risk of venous thromboembolism 
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BMI, body mass index; CI, confidence interval (bars); RR, relative risk; VTE, venous thromboembolism; *, 
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Figure 4. Medical and surgical history comparisons and risk of venous thromboembolism 
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Figure 5. Other medical and surgical history comparisons and risk of venous thromboembolism 
Charlson Comorbidity Index
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1.37 (0.86, 2.18)
1.38 (1.29, 1.46)
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BMI, body mass index; BS, bariatric surgery; CI, confidence interval (bars); OA, osteoarthritis; RA, 
rheumatoid arthritis; RR, relative risk; VTE, venous thromboembolism; *, are number of participants or joint 
replacements 
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Table 1. Summary characteristics of the 89 included studies 
 
Characteristics  
Participants N  
Total number of participants or joint replacements 14,763,963 
Total number of VTE cases 150,086 
Study characteristics  
Location N studies (N participants or joint replacements) 
    North America 39 (14,006,329) 
    Asia 33 (477,404) 
    Europe 14 (383,749) 
    Oceania 3 (1173) 
Study design N studies (N participants or joint replacements) 
    Retrospective cohorts 73 (14,471,062) 
    Prospective cohorts 8 (50,318) 
    Case-control studies 8 (347,275) 
Median (IQR) study quality score 8 (7-8) 
Study level participant characteristics  
Median (IQR) age, years 67.2 (65.2-69.0) 
Median (IQR) % males 35.9 (23.0-41.2) 
Joint type N studies (N participants or joint replacements) 
    Hip and knee 37 (11,575,429) 
    Knee 34 (1,783,042) 
    Hip 18 (1,510,184) 
 
IQR=interquartile range; N, number; VTE, venous thromboembolism 
 
 
 
 
 
  
 
